Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advices EQT VIII in connection with the acquisition of Recover Nordic
Mandate

Vinge advises EQT VIII in connection with the acquisition of Recover Nordic

December 10, 2019 M&A

Vinge has advised EQT VIII in connection with the acquisition of Recover Nordic from funds advised by Agilitas Private Equity.

Recover Nordic is a Nordic market leader in property remediation and environmental services, primarily serving insurance companies, municipalities, industrial- and commercial clients. Headquartered in Oslo, Norway and with more than 90 branches across the Nordics, the Company has over 2,100 employees and is expected to generate revenues of NOK 3.0 billion in 2019.

The transaction is expected to close in the first quarter of 2020.

Vinge’s team consisted of Daniel Rosvall, Johanna Wiberg, Christian Brelin and Ellinor Wargenbrant (M&A), Johan Cederblad and Cornelia Medrek (Environment), Josefine Lanker and Axel Jansson (Banking and Financing), Mathilda Persson, Rebecka Maltenius, Martin Boström and Lisa Hörnqvist (Commercial Agreements and IT), Emma Johansson (Competition and Regulatory), Lisa Ullman and Ebba Svenburg (Employment) and Kristoffer Larson (Real Property).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026